Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Aug 08, 7:15PM CDT
Cramer's watching earnings next week as he seeks stocks worth buying, not selling, in this market.
Final Glance: Biotechnology companies
AP - Fri Aug 08, 5:06PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
3 Biotech Stocks to End Q2 on a Winning Note - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 2:54PM CDT
The rebound was due to strong earnings reports, product approvals, and acquisitions and licensing deals.
Midday Glance: Biotechnology companies
AP - Fri Aug 08, 12:51PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Early Glance: Biotechnology companies
AP - Fri Aug 08, 9:51AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Critical Alerts For Stratasys, Horizon Pharma, Isis Pharmaceuticals, Amgen, and Discover Financial Services Released By InvestorsObserver
PR Newswire - Fri Aug 08, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SSYS, HZNP, ISIS, AMGN, and DFS.
Look for Shares of Amgen to Potentially Rebound after Yesterday's 1.05% Sell Off
Comtex SmarTrend(R) - Thu Aug 07, 3:42PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $125.51 to a high of $128.89. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $126.52 on volume of 3.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Amgen Set to Possibly Rebound After Yesterday's Selloff of 1.05%
Comtex SmarTrend(R) - Thu Aug 07, 3:42PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $125.51 to a high of $128.89. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $126.52 on volume of 3.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NPS Pharma Reports Earnings in Q2 on Strong Gattex Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 11:40AM CDT
NPS Pharma (NPSP) reported earnings of 2 cents in the second quarter , which compared favorably with the Zacks Consensus Estimate.
Ligand Gains on Q2 Earnings Beat, Increases Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 10:32AM CDT
Ligand Pharmaceuticals reported better-than-expected second quarter 2014 results and raised its guidance.
Take Two Interactive, Loews, Amgen, Vertex and Regeneron highlighted as Zacks Bull and Bear of the Day
PR Newswire - Thu Aug 07, 8:30AM CDT
Zacks Equity Research highlights Take Two Interactive (Nasdaq:TTWO-Free Report) as the Bull of the Day and Loews Corp (NYSE:L-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis onAmgen (Nasdaq:AMGN-Free Report), Vertex (Nasdaq:VRTX-Free Report) and Regeneron (Nasdaq:REGN-Free Report).
Biotech Stock Roundup: Amgen Plans Job Cuts, Regeneron's Eylea Continues to Impress - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 06, 11:00AM CDT
Among the earnings reports, the Ebola outbreak has brought quite a few biotech companies into the limelight for their experimental Ebola disease treatments.
Amgen's Multiple Myeloma Drug Kyprolis Succeeds - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 05, 5:21PM CDT
Amgen (AMGN) intends to submit regulatory applications based on this study in the first half of 2015.
'Fast Money' Recap: Is Michael Kors Still in Fashion?
at The Street - Tue Aug 05, 4:00AM CDT
The trading panel looked at Michael Kors' earnings, Microsoft, steel stocks and biotechs.